Drug intelligence / Profile preview

bimin

Development stage: Phase 3
Lead developer: Xiyuan Hospital
Administration: Oral

Overview

Bimin is a Traditional Chinese Medicine (TCM) capsule formulation developed by Xiyuan Hospital of the Chinese Academy of Traditional Chinese Medicine (now the China Academy of Chinese Medical Sciences). It is specifically designed for the treatment of allergic rhinitis. The drug is currently undergoing clinical evaluation, with a Phase I trial (ChiCTR1800017546) initiated to assess the safety and tolerability of single ascending doses in patients. As a botanical-based therapy, its mechanism likely involves the modulation of inflammatory pathways and immune responses associated with nasal hypersensitivity, common in TCM approaches to respiratory allergies.

Brand names: Bimin Capsule
Other names: Bimin capsuleBimin Jiaonang

Targets

CCL20 (C-C motif chemokine ligand 20)CXCL2 (C-X-C motif chemokine ligand 2)IL8 (C-X-C Motif Chemokine Ligand 8)IL1B (Interleukin-1 beta)

Beyond the preview

Go deeper on bimin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bimin.